marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-14-2024
Cyclo Therapeutics Balance Sheet 2011-2024 | CYTH
Annual Balance Sheet Cyclo Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-8.21 M | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt |
22.5 K | - | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.01 M | - | 19.2 K | 17.5 K | 16.4 K | - | - | - | - | 794 K | 56.3 K | 141 K | 27.2 K |
Total Non Current Liabilities |
22.5 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
8.47 M | 3.48 M | 3.83 M | 3.67 M | 3.14 M | - | - | 343 K | 1.01 M | 915 K | 199 K | 319 K | 652 K |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-83.9 M | -63.8 M | -48.3 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
13.2 M | 4.22 M | 19.5 M | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
9.25 M | 1.54 M | 16.6 M | 12.8 M | 2.78 M | 2.22 M | 1.27 M | 960 K | 1.84 M | 2.38 M | 269 K | 22.8 K | 127 K |
Book Value |
13.2 M | 4.22 M | 19.5 M | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
4.76 M | 735 K | 15.7 M | 10.5 M | 936 K | 993 K | 1.15 M | 1.53 M | 3.75 M | 4.37 M | 1.8 M | 1.55 M | 1.42 M |
All numbers in USD currency
Quarterly Balance Sheet Cyclo Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
12.4 K | 17.5 K | 22.5 K | 27.3 K | 31.9 K | 36.5 K | - | - | - | - | - | 4.98 K | 10.4 K | 14.6 K | 18.4 K | 71.1 K | 97.6 K | 18.4 K | 36.1 K | 36.1 K | 36.1 K | 36.1 K | - | - | - | - | - | - | - | - | - | 673 K | 704 K | 704 K | 720 K | 750 K | 765 K | 780 K | 794 K | 749 K | 767 K | 781 K | 795 K | 795 K | 795 K | 795 K | 751 K | 751 K | 751 K | 751 K | 713 K | 713 K | 713 K | 713 K |
Total Non Current Liabilities |
12.4 K | 17.5 K | 22.5 K | 27.3 K | 31.9 K | 36.5 K | - | - | - | - | 18 K | 49.9 K | 82 K | 113 K | 62.9 K | 62.9 K | 62.9 K | 62.9 K | 36.1 K | 36.1 K | 36.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-94.2 M | -88.2 M | -83.9 M | -78.2 M | -73.4 M | -68.8 M | -63.8 M | -58.8 M | -54.6 M | -51.1 M | -48.3 M | -45.6 M | -41.7 M | -38.1 M | -34.1 M | -34.1 M | -34.1 M | -34.1 M | -25.1 M | -25.1 M | -25.1 M | -25.1 M | -17.6 M | -17.6 M | -17.6 M | -17.6 M | -13.3 M | -13.3 M | -13.3 M | -13.3 M | -9.5 M | -9.5 M | -9.5 M | -9.5 M | -5.28 M | -5.28 M | -5.28 M | -5.28 M | -2.72 M | -2.72 M | -2.72 M | -2.72 M | -2.13 M | -2.13 M | -2.13 M | -2.13 M | -2.34 M | -2.34 M | -2.34 M | -2.34 M | -2.41 M | -2.41 M | -2.41 M | -2.41 M |
Total Assets |
4.72 M | 7.16 M | 13.2 M | 5.6 M | 4.64 M | 4.1 M | 4.22 M | 8.49 M | 11.8 M | 15.9 M | 19.5 M | 11.1 M | 14.2 M | 18.1 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 4.11 M | 4.11 M | 4.11 M | 4.11 M | 2.92 M | 2.92 M | 2.92 M | 2.92 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 1.87 M | 1.87 M | 1.87 M | 1.87 M | 4.74 M | 4.69 M | 4.76 M | 4.76 M | 5.29 M | 5.29 M | 5.29 M | 5.29 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M | 2.62 M | 2.62 M | 2.62 M | 2.62 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M |
Cash and Cash Equivalents |
1.12 M | 3 M | 9.25 M | 1.8 M | 842 K | 915 K | 1.54 M | 4.29 M | 7.45 M | 11.8 M | 16.6 M | 8.44 M | 11.5 M | 15.5 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 2.78 M | 2.78 M | 2.78 M | 2.78 M | 2.22 M | 2.22 M | 2.22 M | 2.22 M | 1.27 M | 1.27 M | 1.27 M | 1.27 M | 960 K | 960 K | 960 K | 960 K | 1.84 M | 1.84 M | 1.84 M | 1.84 M | 2.38 M | 2.38 M | 2.38 M | 2.38 M | 269 K | 269 K | 269 K | 269 K | 22.8 K | 22.8 K | 22.8 K | 22.8 K | 127 K | 127 K | 127 K | 127 K |
Book Value |
4.72 M | 7.16 M | 13.2 M | 5.6 M | 4.64 M | 4.1 M | 4.22 M | 8.49 M | 11.8 M | 15.9 M | 19.5 M | 11.1 M | 14.2 M | 18.1 M | 14.2 M | 14.2 M | 14.2 M | 14.2 M | 4.11 M | 4.11 M | 4.11 M | 4.11 M | 2.92 M | 2.92 M | 2.92 M | 2.92 M | 2.09 M | 2.09 M | 2.09 M | 2.09 M | 1.87 M | 1.87 M | 1.87 M | 1.87 M | 4.74 M | 4.69 M | 4.76 M | 4.76 M | 5.29 M | 5.29 M | 5.29 M | 5.29 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M | 2.62 M | 2.62 M | 2.62 M | 2.62 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M |
Total Shareholders Equity |
-5.12 M | 610 K | 4.76 M | -1.05 M | -1.48 M | -439 K | 735 K | 5.61 M | 9.74 M | 13 M | 15.7 M | 7.63 M | -11.1 M | 14.3 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 936 K | 936 K | 936 K | 936 K | 993 K | 993 K | 993 K | 993 K | 1.15 M | 1.15 M | 1.15 M | 1.15 M | 1.53 M | 1.53 M | 1.53 M | 1.53 M | 3.75 M | 3.75 M | 3.75 M | 3.75 M | 4.37 M | 4.37 M | 4.37 M | 4.37 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.55 M | 1.55 M | 1.55 M | 1.55 M | 1.42 M | 1.46 M | 1.42 M | 1.42 M |
All numbers in USD currency